NANOSTRING ($NASDAQ:NSTG): NanoString Technologies, Inc., a leading provider of life science tools for translational research and diagnostics, has seen its stock price slump following a setback in its patent case and the subsequent withdrawal of its guidance. NanoString Technologies provides innovative tools and services that enable researchers and clinicians to gather insights from biological samples. The company’s offerings include instrumentation such as the nCounter system and consumables such as reagents, probes, and kits.
In addition, it provides software applications for the analysis and interpretation of data generated on its platform. NanoString Technologies is headquartered in Seattle, Washington, and its products are used in laboratories around the world. The recent setback in its patent case has caused the company to withdraw its guidance for the coming year. This has caused investors to become uncertain about the company’s future prospects. As a result, the stock price has dropped significantly from its all-time high reached earlier this year. Investors are now watching closely as NanoString Technologies looks to refocus its efforts on developing its research and diagnostic products.
NanoString Technologies‘ stock prices plummeted on Monday, dropping 50.0% from the previous day’s closing price of $1.3 to finish at $0.6. The reason for this sudden fall was a patent setback and the decision to withdraw their guidance. This resulted in a significant drop in the company’s stock prices, with investors becoming increasingly wary. The patent setback was the result of a US Court of Appeals ruling that invalidated two of NanoString Technologies’ patents. This verdict had a negative impact on the company’s stock prices, as it further hampered its ability to protect its intellectual property rights.
This cast further doubt on the company’s financial prospects, leading to a further drop in stock prices. Overall, NanoString Technologies stock slumped following a patent setback and withdrawal of guidance. Investors have responded by selling off their shares, leading to a sharp decline in the stock prices. It remains to be seen how the company will fare in the future and whether it is able to recover from this difficult period. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Nanostring Technologies. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Nanostring Technologies. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Nanostring Technologies. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Nanostring Technologies are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we conducted an analysis of NANOSTRING TECHNOLOGIES‘ wellbeing, and the results are quite interesting. Our star chart shows that NANOSTRING TECHNOLOGIES is strong in asset, medium in growth and weak in dividend and profitability. Based on its performance, we classify NANOSTRING TECHNOLOGIES as a ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. Therefore, we believe that investors looking for steady, moderate returns would be particularly interested in NANOSTRING TECHNOLOGIES. However, the company does have a low health score of 2/10 with regard to its cashflows and debt, so it is less likely to pay off debt and fund future operations. As such, we recommend that potential investors continue to monitor NANOSTRING TECHNOLOGIES’ performance and financials closely. More…
Star Chart Analysis
These companies are all working to develop new and improved methods for diagnosing and treating disease, and the competition between them is fierce. NanoString Technologies Inc has a strong product portfolio and a well-established customer base, but its competitors are quickly catching up. Only time will tell which company will come out on top in this competitive market.
Quanterix Corporation is a biotechnology company that develops and commercializes its proprietary Single Molecule Array technology for use in measurable biomarker analysis. The Company’s SMASH technology is a multiplexing technology that can be used to measure up to hundreds of proteins and other biomarkers in a single reaction. The Company’s products include Simoa HD-1 Analyzer, Simoa Focus Assay Kits, Simoa Control Kits and Simoa Reagents. Quanterix Corporation is headquartered in Lexington, Massachusetts.
– BibbInstruments AB ($LTS:0GIA)
Bibb Instruments AB is a Swedish company that manufactures and markets a range of scientific instruments. The company has a market capitalization of 9.27 million as of 2022 and a return on equity of -18.23%. Bibb Instruments AB is a leading manufacturer of scientific instruments used in research and development, quality control, and manufacturing processes. The company’s products are used in a variety of industries, including pharmaceuticals, food and beverage, cosmetics, and environmental testing.
– Eyebright Medical Technology (Beijing) Co Ltd ($SHSE:688050)
Eyebright Medical Technology (Beijing) Co Ltd is a leading provider of medical devices and solutions in China. The company has a market cap of 24.03B as of 2022 and a return on equity of 9.15%. Eyebright Medical Technology (Beijing) Co Ltd is a leading provider of medical devices and solutions in China. The company provides a wide range of medical devices and solutions for a variety of medical needs.
NanoString Technologies recently experienced a setback when their patent was rejected, leading to a decrease in their stock price. This has caused the company to pull their guidance, resulting in investor uncertainty. Despite this, there are still reasons to be optimistic about NanoString Technologies. Their innovative product line and customer base provide potential for growth, while their cash flow and balance sheet are strong.
In addition, their cash on hand is more than enough to fund their operations. With strategic decisions and continued research and development, investors can expect NanoString Technologies to be a reliable source of potential returns in the future.